{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-242583","form_type":"8-K/A","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2025-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.821487+00:00","generated_at":"2026-05-17T03:23:33.919455+00:00","sec_items":["8.01","9.01","5.02"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xenon names Tucker Kelly CFO with $540k salary, 225k options, 30k RSUs","bullets":["Tucker Kelly appointed CFO effective Oct 15, 2025; replaces interim CFO Ian Mortimer who remains CEO.","Kelly's base salary $540k; eligible for annual incentive up to 45% of base.","Granted inducement option for 225k shares at $41.90 (Oct 15 close) vesting over 4 years.","Granted 30k RSUs vesting 25% annually over 4 years.","Kelly previously CFO of Deciphera, led commercial transition; will support azetukalner launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-242583","json":"https://secwatch.observer/filing/0001193125-25-242583.json","markdown":"https://secwatch.observer/filing/0001193125-25-242583.md","text":"https://secwatch.observer/filing/0001193125-25-242583.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525242583/0001193125-25-242583-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525242583/xene-20251015.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:23:33.919455+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}